Cipla announces reentry into Chinese market with Jiangsu Acebright
Category: #healthcare  By Akshay Kedari  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cipla announces reentry into Chinese market with Jiangsu Acebright

The global pharmaceutical giant Cipla reportedly announced that it has reentered Chinese market in an alliance with Jiangsu Acebright. The company will set up a manufacturing plant for respiratory products in China under the joint venture.

According to reliable sources, both the companies will invest nearly $30 million for the joint venture mutually. Cipla EU, a wholly owned subsidiary of Cipla, will hold an 80 percent share and Acebright will hold a 20 percent share. Even though Cipla will start off with respiratory products in China, it has plans to expand to other segments in the future.  

Umang Vohra, MD & Global CEO, Cipla, reportedly stated that the company is keen to take its well-established knowhow in the respiratory sector to patients in China. Concurrently, the company will explore several means to build a portfolio of products in other therapeutic segments like oncology. Also, it will consider China as an important part of its future roadmap, he further added.

Shengping Xu, Chairman, Acebright Group, reportedly stated that the company has an established partnership of over 20 years with Cipla which shares its vision and approach towards patients.

Apparently, this is not the first time Cipla has entered the Chinese market. In 2012, the pharma major held stakes in three different Chinese companies, 48.2% in Jiangsu-based Cdymax, 16.6% in Shanghai Desano Pharmaceuticals and 25% in Biomab.

Reportedly, Cipla later rejigged its investments letting go of the stake in Cdymax and Biomab. It had sold its stake in Jiangsu-based Cdymax in 2014 for $18.5 million. The share in Hong Kong-based Biomab was sold in 2015 to British Virgin Islands-based Biomab Brilliant for $25.8 million.

Cipla share price has gained 0.54% or 3 points to 553.75 level in afternoon trade on BSE after the announcement. It has recently closed at 550.75 level in trade.

Source credit:

https://www.businesstoday.in/sectors/pharma/cipla-china-joint-venture-jiangsu-acebright/story/364719.html

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-forms-jv-with-jiangsu-acebright-for-respiratory-medicines-in-china/articleshow/70242041.cms?from=mdr

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

GOAT Brand Labs secures USD 36 million in Series A funding round
GOAT Brand Labs secures USD 36 million in Series A funding round
By Akshay Kedari

Apparel-centric platform GOAT Brand Labs has reportedly raised USD 36 million in its first funding r...

Suzuki and Daihatsu planning to join Toyota’s electrification venture
Suzuki and Daihatsu planning to join Toyota’s electrification venture
By Akshay Kedari

Japanese automakers Suzuki Motor Corp. along with Daihatsu Motor Co. Ltd. are joining the commercial...

Aquafarming startup Aquaconnect bags USD 4 Mn in pre-Series A funding
Aquafarming startup Aquaconnect bags USD 4 Mn in pre-Series A funding
By Akshay Kedari

Chennai-based aquaculture startup, Aquaconnect has reportedly raised USD 4 million in a pre-Series A...